| Chen, Lin |
RESCUE-GC, NCT02867839: Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Versus S-1 Alone in Locally Advanced Gastric Cancer |
|
|
| Terminated | 3 | 29 | RoW | Oxaliplatin plus S-1, SOX, S-1 only, S-1 | Peking University Cancer Hospital & Institute | Gastric Cancer | 09/21 | 09/21 | | |
HLX10-006-GCneo, NCT04139135: A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric Cancer |
|
|
| Recruiting | 3 | 642 | RoW | HLX10, Recombinant humanized anti-PD-1 monoclonal antibody injection, Placebos | Shanghai Henlius Biotech | Gastric Cancer | 10/23 | 10/24 | | |
NCT06145893: A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease |
|
|
| Recruiting | 3 | 162 | RoW | Hemay005, Mufemilast, Phosphodiesterase 4 (PDE4) inhibitors, Placebo | Ganzhou Hemay Pharmaceutical Co., Ltd | Behçet's Disease | 11/24 | 03/25 | | |
NCT06477237: Study of Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis |
|
|
| Recruiting | 3 | 400 | RoW | HB0017 Q4W, HB0017 Q8W, placebo | Huabo Biopharm Co., Ltd. | Psoriasis | 08/24 | 12/25 | | |
NCT06775860: ICP-332 in Subjects with Moderate to Severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 552 | RoW | ICP-332 Tablets, ICP-332 Placebo Tablets | Beijing InnoCare Pharma Tech Co., Ltd. | Atopic Dermatitis | 11/26 | 12/26 | | |
NCT05180734: PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer |
|
|
| Active, not recruiting | 3 | 878 | RoW | JS001/Placebo, Postoperative Adjuvant Chemotherapy, JS001/placebo combine with Postoperative Adjuvant Chemotherapy | Shanghai Junshi Bioscience Co., Ltd. | Gastric or Esophagogastric Junction Adenocarcinoma | 06/26 | 07/28 | | |
REACT-AF, NCT05836987: The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation |
|
|
| Recruiting | 3 | 5350 | US | AFSW Guided DOAC, Apple Watch, Continuous DOAC therapy, Oral Anticoagulation therapy | Johns Hopkins University, National Heart, Lung, and Blood Institute (NHLBI) | Atrial Fibrillation | 07/29 | 07/29 | | |
NCT06390748: Esmolol in Sepsis Management:Evaluating Immunomodulatory Effects and Impact on Patient Outcomes |
|
|
| Completed | 2 | 150 | RoW | esmolol | Lin Chen | Sepsis, Lymphocyte Disorder T, Immunologic Paralysis, Catecholamine; Overproduction, Beta-Blocker, Cytokine Storm, Sympathetic Nervous System Diseases | 12/23 | 12/23 | | |
| Recruiting | 2 | 300 | US | Atorvastatin, atorvastatin calcium | Mount Auburn Hospital | COVID-19 | 12/21 | 05/22 | | |
NCT04830644: A Study to Evaluate the Efficacy and Safety of Iguratimod Compared to Placebo in Patients With Active Primary Sjogren's Syndrome. |
|
|
| Recruiting | 2 | 144 | RoW | Iguratimod, Placebo | Jiangsu Simcere Pharmaceutical Co., Ltd. | Primary Sjögren Syndrome | 04/22 | 06/22 | | |
NCT05407246: Phase II Study of Hemay005 in Patients With Active Ankylosing Spondylitis |
|
|
| Completed | 2 | 90 | RoW | Hemay005, placebo | Tianjin Hemay Pharmaceutical Co., Ltd | Active Ankylosing Spondylitis | 08/23 | 08/23 | | |
NCT06250062: A Clinical Study of JS005 in Patients With Ankylosing Spondylitis |
|
|
| Recruiting | 2 | 261 | RoW | Recombinant humanized IL-17A Monoclonal Antibody（JS005）, Placebo（JS005） | Shanghai Junshi Bioscience Co., Ltd., Sponsor GmbH | Ankylosing Spondylitis | 02/25 | 10/25 | | |
NCT05688696: Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus |
|
|
| Recruiting | 2 | 186 | RoW | Orelabrutinib (Low Dose), Orelabrutinib (High Dose), Orelabrutinib Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Systemic Lupus Erythematosus, SLE | 08/25 | 05/26 | | |
NCT05849727: A Clinical Study of TQH3821 Tablets in the Treatment of Treated Rheumatoid Arthritis |
|
|
| Recruiting | 2 | 180 | RoW | TQH3821 tablets 200 mg, TQH3821 tablets matching placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Rheumatoid Arthritis | 06/24 | 12/24 | | |
NCT03273920: Robotic Versus Laparoscopic Distal Gastrectomy With D2 Lymphadenectomy for Locally Advanced Gastric Cancer |
|
|
| Not yet recruiting | N/A | 1110 | RoW | Robotic distal gastrectomy with D2 nodal dissection, Laparoscopic distal gastrectomy with D2 nodal dissection | Southwest Hospital, China, Chinese PLA General Hospital, West China Hospital, Xijing Hospital of Digestive Diseases, Nanjing PLA General Hospital, Peking University Cancer Hospital & Institute, Qingdao University, Fujian Medical University Union Hospital, Central South University, The First Affiliated Hospital of Nanchang University, Sun Yat-sen University, Wuhan Union Hospital, China, Jilin Provincial Tumor Hospital, Lanzhou General Hospital of PLA | Gastric Cancer | 09/19 | 09/22 | | |
CLASS-03a, NCT03468712: Laparoscopic D2 Distal Gastrectomy Following Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancers |
|
|
| Recruiting | N/A | 166 | RoW | Laparoscopic D2 distal gastrectomy | West China Hospital, Peking University Cancer Hospital & Institute, Southern Medical University, China, Shanghai Zhongshan Hospital, Chinese PLA General Hospital, Fujian Medical University Union Hospital, Ruijin Hospital, Southwest Hospital, China, RenJi Hospital, The First Affiliated Hospital with Nanjing Medical University, Fudan University, Tang-Du Hospital, Harbin Medical University, The First Hospital of Jilin University, Guangdong Provincial People's Hospital, Sir Run Run Shaw Hospital | Complications, Postoperative, Surgery--Complications, Cancer of Stomach, Chemotherapy Effect | 04/20 | 04/23 | | |
NCT06379568: Risk of Aspergillus Infection in Patients With Chronic Lung Disease |
|
|
| Completed | N/A | 209 | RoW | No intervention | Lin Chen | Fungal Infection Lungs | 01/24 | 01/24 | | |
NCT06333379: Aspergillosis Detection Via EBC-GM in Ventilated Patients |
|
|
| Completed | N/A | 75 | RoW | Compare the levels of Galactomannan (GM) levels in exhaled breath condensate (EBC) and BALF | Lin Chen | Bronchoalveolar Lavage Fluid, Sensitivity and Specificity, Critical Illness, Respiration Failure, Respiratory Fungal Infection, Exhaled Breath Condensate, Aspergillosis, Invasive Pulmonary | 12/23 | 01/24 | | |
| Recruiting | N/A | 286 | RoW | Antiarrhythmic drug including Propafenone, Sotalol, Dronedarone and Amiodarone, cryoballoon ablation | Ruijin Hospital | Atrial Fibrillation, Persistent, Arrhythmias, Cardiac | 07/25 | 01/26 | | |
NCT05654857: The Prevalence of Family-unit Helicobacter Pylori Infection in Jiangsu |
|
|
| Recruiting | N/A | 4000 | RoW | PCR test in the stool | Nanjing First Hospital, Nanjing Medical University | Helicobacter Pylori Infection | 08/23 | 08/23 | | |
NCT06491966: Clinical Outcomes and Inflammatory Responses in Viral vs. Bacterial Sepsis |
|
|
| Recruiting | N/A | 300 | RoW | observation | Sichuan Provincial People's Hospital | Sepsis, Sepsis Bacterial, Viral Sepsis, Inflammatory Response, Cytokine Storm, COVID-19, MODS | 07/24 | 07/24 | | |
| Not yet recruiting | N/A | 1326 | RoW | observation | Lin Chen, Peking University International Hospital, Chinese PLA General Hospital | Gastric Cancer, Liver Metastases | 07/26 | 12/28 | | |
NCT05389046: Study on the Optimal Diagnosis and Treatment Strategy of Major Depressive Disorder Based on Anhedonia |
|
|
| Recruiting | N/A | 252 | RoW | Escitalopram, Escitalopram+Aripiprazole, Escitalopram+omega-3 PUFAs, Escitalopram+Aripiprazole+omega-3 PUFAs | Peking University | Outpatients / Inpatients With Depression | 12/24 | 12/25 | | |
| Li, Shanshan |
NCT04875169: Evaluate Efficacy and Safety of Oral SHR0302 in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis |
|
|
| Completed | 3 | 336 | Canada, RoW | Core Treatment Active Experimental: SHR0302 Dose#1, Core Treatment Active Experimental: SHR0302 Dose#2, Core Treatment Placebo Comparator: Placebo, Extension Treatment Active Experimental: SHR0302 Dose#1, Extension Treatment Active Experimental: SHR0302 Dose#2 | Reistone Biopharma Company Limited | Atopic Dermatitis | 08/22 | 05/23 | | |
NCT05470413: Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Severe Alopecia Areata |
|
|
| Active, not recruiting | 3 | 330 | RoW | SHR0302, Placebo | Reistone Biopharma Company Limited | Alopecia Areata | 10/23 | 02/24 | | |
NCT06477237: Study of Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis |
|
|
| Recruiting | 3 | 400 | RoW | HB0017 Q4W, HB0017 Q8W, placebo | Huabo Biopharm Co., Ltd. | Psoriasis | 08/24 | 12/25 | | |
NCT06280716: A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 430 | RoW | Placebo, Lebrikizumab, LY3650150, Topical Corticosteroid | Eli Lilly and Company | Atopic Dermatitis | 12/25 | 11/26 | | |
NCT05975268: A Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous JS005 Injection in the Treatment of Adults With Moderate to Severe Chronic Plaque Psoriasis |
|
|
| Active, not recruiting | 3 | 747 | RoW | JS005 (recombinant humanized monoclonal antibody against IL-17A) | Shanghai Junshi Bioscience Co., Ltd. | Moderate to Severe Chronic Plaque Psoriasis | 08/25 | 10/25 | | |
| Recruiting | 3 | 189 | RoW | Roflumilast Cream 0.3%, Zoryve, Vehicle cream | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Plaque Psoriasis | 06/25 | 07/25 | | |
NCT06775860: ICP-332 in Subjects with Moderate to Severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 552 | RoW | ICP-332 Tablets, ICP-332 Placebo Tablets | Beijing InnoCare Pharma Tech Co., Ltd. | Atopic Dermatitis | 11/26 | 12/26 | | |
NCT06631170: Efficacy and Safety of Roflumilast Cream in Subjects with Atopic Dermatitis |
|
|
| Recruiting | 3 | 351 | RoW | Roflumilast Cream 0.15%, Vehicle cream | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Atopic Dermatitis (AD) | 08/25 | 08/25 | | |
VGR-R01-301, NCT06699108: Study to Evaluate the Efficacy and Safety of VGR-R01 Gene Therapy in Patients with Bietti Crystalline Dystrophy |
|
|
| Not yet recruiting | 3 | 45 | RoW | VGR-R01 | Shanghai Vitalgen BioPharma Co., Ltd. | Bietti Crystalline Dystrophy, Inherited Retinal Diseases | 12/26 | 06/27 | | |
NCT05093855: Efficacy and Safety Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) |
|
|
| Completed | 2 | 41 | RoW | BDB-001 Injection | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Hidradenitis Suppurativa | 08/23 | 08/23 | | |
NCT06109818: Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis |
|
|
| Recruiting | 2 | 129 | RoW | ICP-488 Tablets, ICP-488 Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Moderate to Severe Plaque Psoriasis | 10/24 | 11/24 | | |
NCT06077331: A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis |
|
|
| Recruiting | 2 | 120 | RoW | HS-10374 tablets 1mg, HS-10374 tablets 5mg, HS-10374-matched placebo tablets | Hansoh BioMedical R&D Company | Psoriasis | 07/24 | 08/24 | | |
| Recruiting | 2 | 120 | RoW | TQH3906 capsules, Placebo of TQH3906 capsules | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Plaque Psoriasis | 01/25 | 09/25 | | |
NCT05103423: Safety and Efficacy Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) |
|
|
| Completed | 1/2 | 50 | RoW | BDB-001 Injection, Placebo | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Hidradenitis Suppurativa | 07/23 | 07/23 | | |
| Recruiting | N/A | 140 | RoW | sham stimulation, intermittent theta-burst stimulation (iTBS) | Second Affiliated Hospital, School of Medicine, Zhejiang University, Shanghai Mental Health Center, The Affiliated Kangning Hospital of Ningbo University, The First Affiliated Hospital of Anhui Medical University | Posttraumatic Stress Disorder | 12/25 | 05/26 | | |
| Song, Liyu |
NCT06023147: A Real-world Study of the Short-term Efficacy and Safety of E-TACE in Patients With Hepatocellular Carcinoma (HCC) |
|
|
| Not yet recruiting | N/A | 298 | RoW | E-TACE | Xuhua Duan | Hepatocellular Carcinoma | 09/24 | 09/25 | | |
| Li, Yuye |
NCT06477237: Study of Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis |
|
|
| Recruiting | 3 | 400 | RoW | HB0017 Q4W, HB0017 Q8W, placebo | Huabo Biopharm Co., Ltd. | Psoriasis | 08/24 | 12/25 | | |
NCT06109818: Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis |
|
|
| Recruiting | 2 | 129 | RoW | ICP-488 Tablets, ICP-488 Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Moderate to Severe Plaque Psoriasis | 10/24 | 11/24 | | |
| Yang, Yuanyuan |
NCT06552520: To Evaluate the Phase III Clinical Trial of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis |
|
|
| Not yet recruiting | 3 | 500 | RoW | TQH2722 injection, Placebo of TQH2722 injection | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | Atopic Dermatitis | 10/25 | 06/26 | | |
| Recruiting | 2 | 120 | RoW | TQH3906 capsules, Placebo of TQH3906 capsules | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Plaque Psoriasis | 01/25 | 09/25 | | |
